ArticleWorld journal of surgical oncology2025
MED15-TFE3 rearranged renal cell carcinoma: a subtype of TFE3-rearranged renal cell carcinoma with unique clinicopathologic features and better prognosis.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive analysis of six MED15::TFE3 renal cell carcinomas including two novel solid MED15::TFE3 renal cell carcinomas, highlighting their morphologic, immunohistochemical and molecular differences from their cystic counterparts.Virchows Archiv : an international journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMED15-TFE3 rearranged renal cell carcinoma (MED15-TFE3 rRCC) is a rare subtype of TFE3-rearranged renal cell carcinoma (TFE3 rRCC). To date, only 47 cases of MED15-TFE3 rRCC (including 2 cases from our institution) have been reported worldwide.
methodsUsing immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and RNA sequencing, we aimed to identify whether TFE3 rRCC patients at our institution harbor the MED15-TFE3 gene fusion. We will perform a statistical analysis of the pathological features, imaging findings, and clinical outcomes of all published cases of MED 15-TFE rRCC.
resultsMED15-TFE3 rRCC typically has a cystic and solid (predominantly cystic) architecture. The tumor cells feature round nuclei with inconspicuous nucleoli, abundant cytoplasm, and clear to eosinophilic staining. Immunohistochemically, 38 of 39 patients had positive nuclear staining for TFE3, and 37 of 38 patients were positive for PAX8. The FISH assay was positive for rearrangement (red-green signal separation). RNA sequencing identified the MED15-TFE3 fusion gene. One pediatric patient presented with preoperative hilar lymph node metastasis. During follow-up, only one patient developed metastatic disease.
conclusionsIn contrast to traditional TFE3 rRCCs, MED15-TFE3 rRCCs may have distinctive clinicopathological features and a better prognosis. These findings enhance our understanding of the heterogeneity of TFE3 rRCCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.